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Question 
A 73-year-old woman with advanced lung cancer presented to our clinic with increasing pain, 
weakness and weight loss related to metastatic disease involving the liver, lymphatic system and 
skeleton. The patient also complained of increasing difficulty with eating over several weeks. 
Initially, her symptoms were worse with solids, but progressed to involve ingestion of pureed 
food and yoghurt. Constipation was a problem as well. 
Adeno-carcinoma of the lung had been diagnosed by imaging and biopsy of a liver metastasis in 
February 2019. A palliative chemotherapy regime with Cisplatin/Pemetrexed and Binetimib was 
commenced in April 2019; however, staging investigations in July 2019 showed disease 
progression under treatment. Test results also raised concerns that a second cancer in the 
gastrointestinal tract may be present because of increasing anemia (Hb 70g/l), an elevated CEA 
(54.3ng/l), and CA125 (3219U/ml).  
The patient decided against continuation of the chemotherapy. Best supportive care was 
instituted. This included a step-wise increase in opioid therapy with Oxycodon/Naloxon 
20/10mg twice daily with additional oral morphine as required. Constipation was treated with 
osmotic laxatives (Transipeg, Magnesium). Further complementary, anthroposophic medicine 
including rhythmic massage and external application of compresses were applied to relieve her 
abdominal symptoms.  
During her admission, the patient’s swallowing difficulties became acute. She could swallow only 
a few mouthfuls of food or drink before « vomiting » undigested food and secretions. Physical 
examination revealed a cachectic woman with BMI of 17.7kg/ m2. There were dry mucous 
membranes in the mouth, but no sign of candida infection. The oro-pharyngeal swallow was 
intact. The abdomen was soft, slightly tender to palpation with no masses and few belly sounds. 
Rectal digital examination showed no fecal impaction and an abdominal X-ray showed no sign of 
ileus. Laboratory testing revealed no additional abnormalities. 
Endoscopic examination and cross-sectional imaging did not show obstruction or other 
pathology of the oesophagus or mediastinum that could explain the dysphagia (figure 1A/B). 
However, endoscopic functional luminal impedance planimetry (EndoFLIP®; Medtronic) 
suggested reduced distensibility during balloon distension. Due to the severity of the symptoms 
and their impact on her quality of life an esophageal high-resolution manometry (HRM) was 
performed to clarify the diagnosis. This investigation demonstrated premature, simultaneous 
contractions with a short Distal Latency (DL <4.5 s) and abnormal esophago-gastric junction 
(EGJ) function with pathological integrated relaxation pressure (IRP >15 mmHg) well above 
normal levels (figure 1C). A specific treatment was implemented. Two weeks later the patient 
was able to eat most foods without difficulty, EGJ distensibility had increased on EndoFLIP® and 
esophageal motility was normal on repeat HRM investigation (figure 1D).  
Question: What is the diagnosis and what treatment(s) could have been applied? 
 
Answer to: Image 1 (Page YYY):  
The esophageal HRM shows achalasia type III defined by the presence of abnormal EGJ function 
and premature, spastic contractions by the Chicago Classification of oesophageal motility 
disorders (Figure 1C). This finding is consistent also with reduced EGJ distensibility on Endo-
FLIP investigation (Figure 1C). Outlet obstruction by metastases from the primary lung cancer 
(or a second carcinoma) at the EGJ had been excluded by endoscopy and imaging (Figure 1A/B). 
Pseudo-achalasia caused by circulating antibodies to receptors that mediate deglutitive 
relaxation of the esophagus and EGJ was possible; however, this is a very rare condition. Another 
cause of a severe motility disorder in a patient recently prescribed increasing doses of opioid 
analgesia is Opioid-Induced Esophageal Dysfunction (OIED).  
It was not possible to reduce the dose of opioid analgesia in this patient; indeed the dose was 
increased to MST continuous 60mg twice daily following the diagnosis of achalasia. The risk of 
perforation from endoscopy with pneumatic dilatation of the EGJ was considered to be high in 
this cachectic patient and the efficacy of botulinum toxin for the management of achalasia is 
suboptimal. Taking all these factors into account, a therapeutic trial of Naloxegol (Moventig, 
AstraZeneca), a long-acting peripherally acting mu-opioid receptor antagonist (PAMORA), was 
commenced to treat suspected OIED. Because the patient reported no side effects and no 
reduction in analgesia on this medication, the initial dose of 12.5mg was increased in a step-wise 
manner to 50mg once daily (the maximum dose). As the dose of Naloxegol was increased, the 
patient started to eat again with much reduced dysphagia and volume regurgitation. Having 
been able to take only sips of nutrient drinks before this treatment commenced; now she could 
eat soft solid foods without difficulty. The patient consented to a repeat HRM 16 days after the 
initial diagnosis. This demonstrated that the improvement in swallowing function was 
accompanied by a remarkable return to normal esophageal motility and EGJ distensibility 
(figure 1D). Together, the improvement in clinical condition and HRM findings on the peripheral 
opioid antagonist confirmed the diagnosis of OIED. 
Patients taking opioid analgesics often complain about gastrointestinal side effects, in particular 
constipation, due to activation of peripheral opioid receptors , which can cause abnormal 
visceral motility, secretion and sensation. To manage these problems, oral preparations are 
available that combine strong opioids with the short-acting opioid antagonist Naloxone (Targin, 
Purdue Pharma) that does not cross the blood-brain barrier. Recently once daily dosing with 
long-acting Naloxegol (AstraZeneca) has been approved by regulatory bodies for the treatment 
of opioid-induced constipation (OIC) in patients with chronic pain syndromes. 
Recently it has been recognized that opioid treatment is also a cause of esophageal symptoms 
including dysphagia, reflux symptoms and chest pain. Case series from the Mayo Clinic in 
Scottsdale Arizona report that approximately 1 in 4 patients taking opioids referred for HRM 
have a major motility disorder compared to 1 in 10 patients overall.[1, 2] Patients on these 
medications have higher prevalence of achalasia, EGJ outflow obstruction, distal esophageal 
spasm and jackhammer esophagus.[1, 2] The prevalence of OIED is dose-dependent and more 
common in patients taking strong opioids (e.g. oxycodone) compared to tramadol (31% vs. 
12%)).[2] There is also an increase in OIED for patients who were studied on opioids (last dose 
within 24 hours of HRM), compared to chronic users studied off opioids (last dose ≥24 hours 
from HRM) (33% vs. 15%).[1, 2] 
Because the mechanism underlying the effects of opioids on esophageal motility have not been 
fully clarified, it can be hard to differentiate between primary, idiopathic achalasia and 
secondary, iatrogenic disease. Physiological and clinical studies have shown that patients with 
OIED have different responses to amyl nitrite and cholecystokinin.[3] Based on these 
observations it has been suggested that opioids inhibit nitric oxide releasing neurons in the 
esophagus allowing unopposed excitatory input from cholinergic neurons leading to the 
impaired EGJ relaxation, and premature, spastic esophageal contractions. 
With the exception of dose-reduction or withdrawal of opioids there is no established treatment 
for OIED.  Furthermore, conventional therapies (pneumatic dilatation or myotomy) that are 
known to be effective for achalasia have disappointing results in this patient group. Given the 
difficulty in reducing analgesic medication in patients with chronic pain, it is appropriate to 
consider the use of peripheral opiate antagonists such as naloxegol in the management of OIED. 
To our knowledge, this is the first case report of the successful use of naloxegol (or any 
PAMORA) in this condition. Our experience indicates that this medication can provide effective 
relief of symptomatic OIED in a palliative situation, where opioids cannot easily be withdrawn. 
Pneumatic dilatation, surgical myotomy, or per-oral endoscopic myotomy should be reserved for 
refractory cases and should be pursued with caution, after review of risks and benefits with the 
patients given reports of lower response rates in this patient group. 
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